Page last updated: 2024-10-23

2,2-bis(4-glycidyloxyphenyl)propane and Huntington Disease

2,2-bis(4-glycidyloxyphenyl)propane has been researched along with Huntington Disease in 1 studies

2,2-bis(4-glycidyloxyphenyl)propane: structure

Huntington Disease: A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kalonia, H1
Kumar, P1
Kumar, A1

Other Studies

1 other study available for 2,2-bis(4-glycidyloxyphenyl)propane and Huntington Disease

ArticleYear
Pioglitazone ameliorates behavioral, biochemical and cellular alterations in quinolinic acid induced neurotoxicity: possible role of peroxisome proliferator activated receptor-Upsilon (PPARUpsilon) in Huntington's disease.
    Pharmacology, biochemistry, and behavior, 2010, Volume: 96, Issue:2

    Topics: Animals; Antioxidants; Benzhydryl Compounds; Body Weight; Corpus Striatum; Disease Models, Animal; E

2010